VOR: vorbio.com Expected earnings per share growth for next year

By attracting top bioinformaticians and cell engineering experts, the projected EPS growth for next year demonstrates strong momentum. The value of 50.60 reflects the current magnitude of this forecast. Vor Biopharma Inc. (VOR) leads in bone marrow modification for systemic protection by investing in gene editing. The development of shielding stem cells enables the use of aggressive chemotherapy, attracting the attention of pharmaceutical behemoths.

Vor Bio (VOR): Expected net earnings per share growth next year from 07/04/2022 to 11/14/2026

vorbio.com - analytical breakdowns and key metrics (VOR)

- share price and consensus valuation forecast:

Stock Price Vor Bio|VOR - Broker Consensus Forecast

- market capitalization information:

Market Valuation Vor Biopharma|VOR - Total Company Value

- book capitalization information:

Net Assets per Single Share Vor Biopharma|VOR - Total Stockholders' Equity|Market Value to Book Value Ratio vorbio.com|VOR - Aggregate Asset Value

- debt and solvency information:

- net income and valuation ratios data:

VOR - Profit After Tax|Projected Future Earnings Vor Biopharma Inc.|VOR - Company Value to Net Income|Forward P/E Multiple Vor Biopharma Inc.|VOR - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vor Biopharma|VOR - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Vor Biopharma|VOR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth vorbio.com|VOR - Earnings growth in current year|Expected earnings per share growth for next year Vor Biopharma Inc.

- total revenue and sales volume data:

VOR - Company Sales Revenue|Projected Sales Volume Vor Bio|VOR - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Vor Biopharma

Summary company analysis:Vor Bio, VOR

Vor Biopharma Inc. (VOR) is developing scientific alliances with oncology centers to optimize cell therapy for blood cancer. The success of these studies directly impacts the revision of expected net income that analysts project for future periods. This indicator measures the dynamics of the EPS consensus forecast, reflecting market expectations for the business's profitability over the next year. A decline in the consensus earnings per share forecast change signals a drop in the issuer's fundamental attractiveness.

Competitor analysis